Your session is about to expire
← Back to Search
Rifaximin for Hepatic Encephalopathy
Study Summary
This trial will study the effects of Rifaximin on patients with Cirrhosis who have Small Intestinal Bacterial Overgrowth (SIBO) and Covert Hepatic Encephalopathy (CHE).
- Minimal Hepatic Encephalopathy
- Small Intestinal Bacterial Overgrowth
- Gastroparesis
- Liver Cirrhosis
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 222 Patients • NCT01842581Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this research project have an age limit?
"The age requirement for this trial is 18-89. There are a total of 147 studies involving people younger than 18 and 548 with elderly patients."
Are people with the required medical condition still able to join this trial?
"That is correct, the clinical trial detailed on clinicaltrials.gov is currently looking for 20 participants at 1 location. The listing was first posted on September 15th, 2021 and edited most recently on November 23rd, 2021."
What are the common conditions that Rifaximin is used to address?
"Rifaximin is primarily used to treat clostridium difficile infection recurrence. It can also be useful in managing symptoms for patients with irritable bowel syndrome (IBS), bacterial infections, and diarrhea."
How many individuals are enrolled in this experiment?
"That is accurate. The listing for this clinical trial on clinicaltrials.gov specifies that the trial is currently ongoing, with 20 patients being recruited from a single location. The listing was created on 9/15/2021 and updated as recently as 11/23/2021."
Who might be most benefited by participating in this research?
"20 participants who meet the following criteria are needed for this study: must be between 18-89 years old, have an upper gastrointestinal motility disorder, and cannot have had a transjugular intrahepatic portosystemic shunt (TIPS) placed or prior overt hepatic encephalopathy. Furthermore, these patients must also test positive for CHE [two of the following should be abnormal as compared to healthy controls: number connection test A/B (NCT-A/B), Digit Symbol Test (DST), or Block Design Test (BDT)] at least 2 months prior to the start of the study"
What are the probability of harmful side effects from taking Rifaximin?
"There is both efficacy and safety data supporting Rifaximin, thus it received a score of 3."
Share this study with friends
Copy Link
Messenger